PLX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 10.9% beat Armata Pharmaceuticals's return on equity of --.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 879.02%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Protalix BioTherapeutics has a beta of -0.227, which suggesting that the stock is 122.694% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Protalix BioTherapeutics's net income of -$3.6M is higher than Armata Pharmaceuticals's net income of -$6.5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 35.75x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.01x versus 1,000.03x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of 10.9% beat Perspective Therapeutics's return on equity of --.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 879.02%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Protalix BioTherapeutics has higher upside potential than Perspective Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Perspective Therapeutics.

Protalix BioTherapeutics has a beta of -0.227, which suggesting that the stock is 122.694% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Protalix BioTherapeutics's net income of -$3.6M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 35.75x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.01x versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of 12.06%. Protalix BioTherapeutics's return on equity of 10.9% beat Electromed's return on equity of 16.57%.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 879.02%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 81.87%. Given that Protalix BioTherapeutics has higher upside potential than Electromed, analysts believe Protalix BioTherapeutics is more attractive than Electromed.

Protalix BioTherapeutics has a beta of -0.227, which suggesting that the stock is 122.694% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are smaller than Electromed quarterly revenues of $15.7M. Protalix BioTherapeutics's net income of -$3.6M is lower than Electromed's net income of $1.9M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 35.75x while Electromed's PE ratio is 23.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.01x versus 2.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -35.79% compared to Protalix BioTherapeutics's net margin of 0.18%. Protalix BioTherapeutics's return on equity of 10.9% beat Xtant Medical Holdings's return on equity of -26.62%.

Protalix BioTherapeutics has a consensus price target of $14.00, signalling upside risk potential of 879.02%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Protalix BioTherapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Protalix BioTherapeutics is more attractive than Xtant Medical Holdings.

Protalix BioTherapeutics has a beta of -0.227, which suggesting that the stock is 122.694% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Protalix BioTherapeutics quarterly revenues are $10.1M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Protalix BioTherapeutics's net income of -$3.6M is lower than Xtant Medical Holdings's net income of $58K. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 35.75x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 2.01x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.